Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/6389
Title: Intra-Cavernosal Injection of Botulinum Toxin in the Treatment of Erectile Dysfunction: a Systematic Review and Meta-Analysis
Authors: Abou Zahr, Rawad
Bou Kheir, George
Mjaess, Georges
Jabbour, Teddy
Chalhoub, Khalil
Diamand, Romain
Roumeguère, Thierry
Affiliations: Faculty of Medicine 
Issue Date: 2022
Publisher: Elsevier
Part of: Urology
Volume: 170
Start page: 5
End page: 13
Abstract: 
OBJECTIVE
To evaluate the role of botulinum toxin in treating erectile dysfunction as a novel treatment strategy avoiding morbid and irreversible surgeries.

METHODS
A systematic review of literature was conducted from January 1990 through July 31, 2021. Search engines used included PubMed, Embase and Medline databases, to identify studies investigating botulinum toxin in erectile dysfunction, published in English. Seven studies in total were included in our review including two pre-clinical studies. A meta-analysis was performed on three outcomes included commonly in at least two studies. Among the different parameters assessed were, Erection Hardness Score (EHS), Peak Systolic Velocity in cavernosal artery (PSV) and the Sexual Health Inventory for Men (SHIM) score.

RESULTS
A clear benefit was noted for intracavernosal injection (ICI) of botulinum toxin (BoNT-A) on PSV with a mean difference (MD) of 10.82 [4.99, 16.65] and a heterogeneity of I2=61%. EHS results favored BoNT-A as well over placebo with a MD of 0.7 [0.47, 0.93] and heterogeneity of I2=94%. As for SHIM score, with a heterogeneity of I2=85%, no statistically significant difference was found (MD 0.58 [-0.03, 1.20]).

CONCLUSION
Our review and meta-analysis have shown statistical significance for the benefit of BoNT-A in terms of EHS and PSV. However, this statistical significance should be interpreted in light of the given limitations: small sample size, heterogeneity in data collection, patient selection bias, and clinical significance of the measured differences. ICI of BoNT-A should currently be limited to clinical studies to further elucidate its clinical benefit.
URI: https://scholarhub.balamand.edu.lb/handle/uob/6389
DOI: 10.1016/j.urology.2022.08.039
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record

Record view(s)

9
checked on Feb 5, 2023

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.